DivestmentJul 6, 2026, 06:08 AM
Clarivate Sells Life Sciences & Healthcare Segment for $600M
AI Summary
Clarivate Plc announced a definitive agreement to divest its Life Sciences & Healthcare segment to an affiliate of Altaris, LLC for $600 million. The company intends to use the cash proceeds to reduce debt, aiming to strengthen its balance sheet and improve its financial profile by increasing recurring revenue mix, expanding Adjusted EBITDA margin, and lowering capital intensity. Clarivate reaffirmed its full-year 2026 financial outlook, with the transaction expected to close by year-end 2026.
Key Highlights
- Clarivate agreed to sell its Life Sciences & Healthcare segment to Altaris LLC for $600 million.
- The transaction includes $500 million in cash at closing, $25 million deferred cash, and a $75 million seller note.
- Proceeds will be used to reduce debt, strengthening the balance sheet.
- The divestment is expected to enhance the recurring revenue mix, expand Adjusted EBITDA margin, and lower capital intensity.
- Clarivate reaffirmed its full-year 2026 financial outlook, including the LS&H segment results.
- The company expects to record a non-cash goodwill impairment of approximately $225 million to $250 million.
- The transaction is expected to close by the end of 2026, subject to customary conditions.
Price Impact
More from CLVT